Agilent pd-l1 ihc 22c3 pharmdx expands ce-ivd mark in non-small cell lung cancer (nsclc)

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced that the company's pd-l1 ihc 22c3 pharmdx assay is now labeled for expanded use in patients with non-small cell lung cancer (nsclc) in the european union. pd-l1 ihc 22c3 pharmdx can now be used as an aid in identifying nsclc patients with tumor pd-l1 expression of tumor proportion score (tps) ≥ 50% for treatment with libtayo® (cemiplimab). this announcement underscores agilent's continuing commitment to th
A Ratings Summary
A Quant Ranking